Bictegravir - Revision history

Alexander Berchansky at 12:32, 29 August 2023

Alexander Berchansky — Tue, 29 Aug 2023 12:32:30 GMT

←Older revision		Revision as of 12:32, 29 August 2023
Line 2:		Line 2:
	Bictegravir (INN; BIC, formerly known as GS-9883) is a second-generation integrase inhibitor (INSTI) class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences. See also [https://en.wikipedia.org/wiki/Bictegravir Bictegravir].		Bictegravir (INN; BIC, formerly known as GS-9883) is a second-generation integrase inhibitor (INSTI) class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences. See also [https://en.wikipedia.org/wiki/Bictegravir Bictegravir].

-	In 2016, bictegravir was in a Phase 3 trial as part of a single tablet regimen in combination with tenofovir alafenamide (TAF) and emtricitabine (FTC) for the treatment of HIV-1 infection<ref name="a5">[https://www.gilead.com/news-and-press/press-room/press-releases/2016/6/gilead-presents-preliminary-data-on-bictegravir-an-investigational-integrase-strand-transfer-inhibitor-for-the-treatment-of-hiv "Press Release: Gilead Presents Preliminary Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV \| Gilead".] Gilead. 20 June 2016. Archived from the original on 2 February 2017. Retrieved 20 January 2017.</ref> and the combination drug bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) was approved for use in the United States in 2018.<ref name="a6">[https://www.businesswire.com/news/home/20180207006071/en/U.S.-Food-Drug-Administration-Approves-Gilead%E2%80%99s-Biktarvy%C2%AE "U.S. Food and Drug Administration Approves Gilead's Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection"] (Press release). Gilead. 7 February 2018.</ref>	+	In 2016, bictegravir was in a Phase 3 trial as part of a single tablet regimen in combination with tenofovir alafenamide (TAF) and emtricitabine (FTC) for the treatment of HIV-1 infection<ref name="a5">[https://www.gilead.com/news-and-press/press-room/press-releases/2016/6/gilead-presents-preliminary-data-on-bictegravir-an-investigational-integrase-strand-transfer-inhibitor-for-the-treatment-of-hiv "Press Release: Gilead Presents Preliminary Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV \| Gilead".] Gilead. 20 June 2016. Archived from the original on 2 February 2017. Retrieved 20 January 2017.</ref> and the combination drug bictegravir/[[emtricitabine]]/tenofovir alafenamide (Biktarvy) was approved for use in the United States in 2018.<ref name="a6">[https://www.businesswire.com/news/home/20180207006071/en/U.S.-Food-Drug-Administration-Approves-Gilead%E2%80%99s-Biktarvy%C2%AE "U.S. Food and Drug Administration Approves Gilead's Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection"] (Press release). Gilead. 7 February 2018.</ref>

	<scene name='98/989308/Overall/2'>Structure of the STLV intasome:B56 complex bound to the strand-transfer inhibitor bictegravir</scene> ([[7ouh]]).		<scene name='98/989308/Overall/2'>Structure of the STLV intasome:B56 complex bound to the strand-transfer inhibitor bictegravir</scene> ([[7ouh]]).

Alexander Berchansky at 12:42, 28 August 2023

Alexander Berchansky — Mon, 28 Aug 2023 12:42:59 GMT

←Older revision		Revision as of 12:42, 28 August 2023
Line 5:		Line 5:

	<scene name='98/989308/Overall/2'>Structure of the STLV intasome:B56 complex bound to the strand-transfer inhibitor bictegravir</scene> ([[7ouh]]).		<scene name='98/989308/Overall/2'>Structure of the STLV intasome:B56 complex bound to the strand-transfer inhibitor bictegravir</scene> ([[7ouh]]).
		+
		+	<scene name='98/989308/Overall/4'>Bictegravir inhibits integrase</scene>.

	</StructureSection>		</StructureSection>
	== References ==		== References ==
	<references/>		<references/>

Alexander Berchansky at 12:21, 28 August 2023

Alexander Berchansky — Mon, 28 Aug 2023 12:21:27 GMT

←Older revision		Revision as of 12:21, 28 August 2023
Line 2:		Line 2:
	Bictegravir (INN; BIC, formerly known as GS-9883) is a second-generation integrase inhibitor (INSTI) class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences. See also [https://en.wikipedia.org/wiki/Bictegravir Bictegravir].		Bictegravir (INN; BIC, formerly known as GS-9883) is a second-generation integrase inhibitor (INSTI) class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences. See also [https://en.wikipedia.org/wiki/Bictegravir Bictegravir].

-	In 2016, bictegravir was in a Phase 3 trial as part of a single tablet regimen in combination with tenofovir alafenamide (TAF) and emtricitabine (FTC) for the treatment of HIV-1 infection<ref name="a5">[https://www.gilead.com/news-and-press/press-room/press-releases/2016/6/gilead-presents-preliminary-data-on-bictegravir-an-investigational-integrase-strand-transfer-inhibitor-for-the-treatment-of-hiv "Press Release: Gilead Presents Preliminary Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV \| Gilead".] Gilead. 20 June 2016. Archived from the original on 2 February 2017. Retrieved 20 January 2017.</ref> and the combination drug bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) was approved for use in the United States in 2018.[6]	+	In 2016, bictegravir was in a Phase 3 trial as part of a single tablet regimen in combination with tenofovir alafenamide (TAF) and emtricitabine (FTC) for the treatment of HIV-1 infection<ref name="a5">[https://www.gilead.com/news-and-press/press-room/press-releases/2016/6/gilead-presents-preliminary-data-on-bictegravir-an-investigational-integrase-strand-transfer-inhibitor-for-the-treatment-of-hiv "Press Release: Gilead Presents Preliminary Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV \| Gilead".] Gilead. 20 June 2016. Archived from the original on 2 February 2017. Retrieved 20 January 2017.</ref> and the combination drug bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) was approved for use in the United States in 2018.<ref name="a6">[https://www.businesswire.com/news/home/20180207006071/en/U.S.-Food-Drug-Administration-Approves-Gilead%E2%80%99s-Biktarvy%C2%AE "U.S. Food and Drug Administration Approves Gilead's Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection"] (Press release). Gilead. 7 February 2018.</ref>

	<scene name='98/989308/Overall/2'>Structure of the STLV intasome:B56 complex bound to the strand-transfer inhibitor bictegravir</scene> ([[7ouh]]).		<scene name='98/989308/Overall/2'>Structure of the STLV intasome:B56 complex bound to the strand-transfer inhibitor bictegravir</scene> ([[7ouh]]).

Alexander Berchansky at 12:19, 28 August 2023

Alexander Berchansky — Mon, 28 Aug 2023 12:19:46 GMT

←Older revision		Revision as of 12:19, 28 August 2023
Line 2:		Line 2:
	Bictegravir (INN; BIC, formerly known as GS-9883) is a second-generation integrase inhibitor (INSTI) class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences. See also [https://en.wikipedia.org/wiki/Bictegravir Bictegravir].		Bictegravir (INN; BIC, formerly known as GS-9883) is a second-generation integrase inhibitor (INSTI) class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences. See also [https://en.wikipedia.org/wiki/Bictegravir Bictegravir].

-	In 2016, bictegravir was in a Phase 3 trial as part of a single tablet regimen in combination with tenofovir alafenamide (TAF) and emtricitabine (FTC) for the treatment of HIV-1 infection[5] and the combination drug bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) was approved for use in the United States in 2018.[6]	+	In 2016, bictegravir was in a Phase 3 trial as part of a single tablet regimen in combination with tenofovir alafenamide (TAF) and emtricitabine (FTC) for the treatment of HIV-1 infection<ref name="a5">[https://www.gilead.com/news-and-press/press-room/press-releases/2016/6/gilead-presents-preliminary-data-on-bictegravir-an-investigational-integrase-strand-transfer-inhibitor-for-the-treatment-of-hiv "Press Release: Gilead Presents Preliminary Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV \| Gilead".] Gilead. 20 June 2016. Archived from the original on 2 February 2017. Retrieved 20 January 2017.</ref> and the combination drug bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) was approved for use in the United States in 2018.[6]

	<scene name='98/989308/Overall/2'>Structure of the STLV intasome:B56 complex bound to the strand-transfer inhibitor bictegravir</scene> ([[7ouh]]).		<scene name='98/989308/Overall/2'>Structure of the STLV intasome:B56 complex bound to the strand-transfer inhibitor bictegravir</scene> ([[7ouh]]).

Alexander Berchansky at 12:16, 28 August 2023

Alexander Berchansky — Mon, 28 Aug 2023 12:16:54 GMT

←Older revision		Revision as of 12:16, 28 August 2023
Line 1:		Line 1:
	<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='98/989308/Cv/1'>		<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='98/989308/Cv/1'>
	Bictegravir (INN; BIC, formerly known as GS-9883) is a second-generation integrase inhibitor (INSTI) class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences. See also [https://en.wikipedia.org/wiki/Bictegravir Bictegravir].		Bictegravir (INN; BIC, formerly known as GS-9883) is a second-generation integrase inhibitor (INSTI) class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences. See also [https://en.wikipedia.org/wiki/Bictegravir Bictegravir].
		+
		+	In 2016, bictegravir was in a Phase 3 trial as part of a single tablet regimen in combination with tenofovir alafenamide (TAF) and emtricitabine (FTC) for the treatment of HIV-1 infection[5] and the combination drug bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) was approved for use in the United States in 2018.[6]

	<scene name='98/989308/Overall/2'>Structure of the STLV intasome:B56 complex bound to the strand-transfer inhibitor bictegravir</scene> ([[7ouh]]).		<scene name='98/989308/Overall/2'>Structure of the STLV intasome:B56 complex bound to the strand-transfer inhibitor bictegravir</scene> ([[7ouh]]).

Alexander Berchansky at 12:14, 28 August 2023

Alexander Berchansky — Mon, 28 Aug 2023 12:14:09 GMT

←Older revision		Revision as of 12:14, 28 August 2023
Line 1:		Line 1:
	<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='98/989308/Cv/1'>		<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='98/989308/Cv/1'>
	Bictegravir (INN; BIC, formerly known as GS-9883) is a second-generation integrase inhibitor (INSTI) class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences. See also [https://en.wikipedia.org/wiki/Bictegravir Bictegravir].		Bictegravir (INN; BIC, formerly known as GS-9883) is a second-generation integrase inhibitor (INSTI) class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences. See also [https://en.wikipedia.org/wiki/Bictegravir Bictegravir].
		+
		+	<scene name='98/989308/Overall/2'>Structure of the STLV intasome:B56 complex bound to the strand-transfer inhibitor bictegravir</scene> ([[7ouh]]).

	</StructureSection>		</StructureSection>
	== References ==		== References ==
	<references/>		<references/>

Alexander Berchansky at 13:30, 27 August 2023

Alexander Berchansky — Sun, 27 Aug 2023 13:30:19 GMT

←Older revision		Revision as of 13:30, 27 August 2023
Line 1:		Line 1:
	<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='98/989308/Cv/1'>		<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='98/989308/Cv/1'>
-	Bictegravir (INN; BIC, formerly known as GS-9883)~~[1][2]~~ is a second-generation integrase inhibitor (INSTI) class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences. See also [https://en.wikipedia.org/wiki/Bictegravir Bictegravir].	+	Bictegravir (INN; BIC, formerly known as GS-9883) is a second-generation integrase inhibitor (INSTI) class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences. See also [https://en.wikipedia.org/wiki/Bictegravir Bictegravir].

	</StructureSection>		</StructureSection>
	== References ==		== References ==
	<references/>		<references/>

Alexander Berchansky at 13:30, 27 August 2023

Alexander Berchansky — Sun, 27 Aug 2023 13:30:03 GMT

←Older revision		Revision as of 13:30, 27 August 2023
Line 1:		Line 1:
-	<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''>	+	<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='98/989308/Cv/1'>
	Bictegravir (INN; BIC, formerly known as GS-9883)[1][2] is a second-generation integrase inhibitor (INSTI) class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences. See also [https://en.wikipedia.org/wiki/Bictegravir Bictegravir].		Bictegravir (INN; BIC, formerly known as GS-9883)[1][2] is a second-generation integrase inhibitor (INSTI) class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences. See also [https://en.wikipedia.org/wiki/Bictegravir Bictegravir].

Alexander Berchansky: New page: Bictegravir (INN; BIC, formerly known as GS-9883)[1][2] is a second-generation integrase in...

Alexander Berchansky — Sun, 27 Aug 2023 13:26:40 GMT

New page: <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''> Bictegravir (INN; BIC, formerly known as GS-9883)[1][2] is a second-generation integrase in...

New page

<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''>
Bictegravir (INN; BIC, formerly known as GS-9883)[1][2] is a second-generation integrase inhibitor (INSTI) class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences. See also [https://en.wikipedia.org/wiki/Bictegravir Bictegravir].

</StructureSection>
== References ==
<references/>